IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd., and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 21, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceutical Holdings Ltd., ("Kitov" or the "Company") (KTOV). Investors, who purchased or otherwise acquired Kitov shares between November 20, 2015 and February 3, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff deadline.
To participate in this class action lawsuit, please click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On February 6, 2017, the Israeli publication Calcalist announced that Kitov's Chief Executive Officer, Isaac Israel, had been held by the Israeli Securities Authority in response to allegations of publishing misleading information about a recent clinical trial of one of Kitov's products. When this information was disclosed to the investing public, the value of Kitov stock fell, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
SOURCE: Lundin Law PC
